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Are baseline ultrasound and
mammographic features associated with
rates of pathological completes response in
patients receiving neoadjuvant
chemotherapy for breast cancer?
Sarah L. Savaridas1,2* , Yee Ting Sim2, Sarah J. Vinnicombe3, Colin A. Purdie2, Alastair M. Thompson4 and
Andy Evans1,2
Abstract
Background: Increasing numbers of breast cancer patients receive neoadjuvant chemotherapy (NACT). We seek to
investigate whether baseline mammographic and ultrasound features are associated with complete pathological
response (pCR) after NACT.
Methods: A database of NACT patients was reviewed. Baseline imaging parameters assessed were ultrasound:
posterior effect; echo pattern; margin and lesion diameter; mammography: spiculation and microcalcification. Core
biopsy grade and immunophenotype were documented. Data were analysed for the whole study group and by
immunophenotype.
Results: Of the 222 cancers, 83 (37%) were triple negative (TN), 61 (27%) ER positive/HER-2 negative and 78 (35%)
HER-2 positive. A pCR occurred in 46 of 222 cancers (21%). For the whole group, response was associated with high
core biopsy grade (grade 3 vs. grade 1 or 2) (26% vs. 9%, p = 0.0044), absence of posterior shadowing on ultrasound
(26% vs. 10%, p < 0.001) and the absence of mammographic spiculation (26 vs. 6%, p < 0.001). Within the HER-2
positive group; the absence of shadowing and spiculation remained highly associated with pCR, in addition to small
ultrasound size (AUC = 0.71, p < 0.001) and the absence of microcalcification (39% vs. 21%, p < 0.02). On multivariable
analysis absence of spiculation and core grade remained significant for the whole cohort, size and absence of
spiculation remained significant for HER-2 positive tumours. No feature predicted pCR in TN tumours.
Conclusion: A pCR is less likely when there is mammographic spiculation. Small ultrasound size is associated with pCR
in HER-2 positive tumours. These findings may be helpful when discussing NACT and surgical options with patients.
Trial registration: UK Clinical Trials Gateway: registration number 16712.
Keywords: Breast carcinoma, Neoadjuvant chemotherapy, Pathological complete response, Mammography,
Ultrasound
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Background
Increasing numbers of breast cancer patients are now re-
ceiving neoadjuvant chemotherapy (NACT). Whilst in
some patients this results in down-staging of an initially
inoperable tumour or reduces the extent of surgery re-
quired in the breast and axilla, others derive little, if any,
benefit from NACT yet experience the associated morbid-
ity of treatments. Patients might choose to have chemo-
therapy post operatively if they were aware that NACT
was unlikely to result in a sufficiently good response to
alter the surgical plan. Currently the only predictors of re-
sponse used routinely are the immunophenotype of the
tumour and core biopsy tumour grade. However, large
variations are seen in chemo(in)sensitivity within immu-
nophenotypes and tumours of the same grade. Therefore,
increasing the physician’s ability to predict at baseline the
response to NACT would be helpful for patient selection.
Various genetic and immunohistochemical tumour
factors have been proposed to aid prediction of re-
sponse, however these remain imperfect and are not in
routine use [1–3]. There are a few published studies
assessing features of baseline MRI scans, demonstrating
that well-defined and round/oval tumours, absence of
intra-tumoural high T2 signal intensity and absence of
peri-tumoural oedema correlate with better response to
NACT [4–6]. Evidence pertaining to baseline ultrasound
and mammography, however, remains scant. Two recent
papers considered triple negative cancers alone; one
study of 328 patients found the presence of microcalcifi-
cation on the initial mammogram was significantly asso-
ciated with residual disease (presumed to include in-situ
disease) [7]. A further study comparing tumours that
completely responded to tumours with residual in-situ
disease following NACT found that the absence of mam-
mographic microcalcification, round shape and posterior
enhancement on baseline ultrasound were significantly
more common amongst tumours which demonstrated
pCR with no residual in-situ disease [8]. However, in
neither study, were these findings significant on multi-
variable analysis. To our knowledge there is no pub-
lished evidence regarding baseline mammographic or
ultrasound imaging features and response prediction in
other breast cancer immunophenotypes. Mammography
(MMG) and ultrasound (US) are almost universally per-
formed at diagnosis, prior to treatment decisions and
the commencement of NACT. Thus, if it were possible
to identify baseline imaging features associated with
treatment response this would provide an inexpensive
and readily available guide for the treating team. Our
aim was therefore to identify associations between base-
line US features, mammographic characteristics and
other tumour parameters routinely available pre-
treatment and pCR in women receiving NACT both as a
whole and according to immunophenotype.
Methods
This was a retrospective review of data collected as part
of an ethically-approved prospective breast cancer im-
aging study (REC no. 14/ES/0047). Women over the age
of 18 years with invasive breast cancer receiving NACT
were included after written informed consent. All pa-
tients were metastasis free at the start of treatment.
Baseline ultrasound (US) and mammography (MMG)
was performed at diagnosis. Ultrasound was performed
on SuperSonic Imagine (SuperSonic, Aix-en-Provence
France). Mammograms were performed on either Holo-
gic Selina Dimensions (Hologic, Bedford, Massachusetts)
or Seimans Mammomat Inspiration (Seimans-Healthi-
neers, Erlangen, Germany) Imaging was assessed by
independently by two experienced breast radiologists
who were blinded to the treatment outcomes. US im-
aging features documented included posterior effect
(shadowing, no effect or enhancement), echo pattern
(hypoechoic, hyperechoic or heterogeneous), maximum
lesion size and whether the lesion had circumscribed
margins.
The MMG features documented were the presence or
absence of spiculation (the presence of either distortion
or a spiculate mass) and tumour-associated microcalcifi-
cation. Estimated tumour grade and tumour immuno-
phenotype as assessed on diagnostic core biopsy were
documented as these factors are available at baseline as-
sessment. The HER-2 positive group included those with
ER and/or PR positivity, therefore the ER positive group
does not include ER positive tumours which were also
HER-2 positive. Complete pathological response (pCR)
was defined as the absence of invasive disease in both
the breast and the axilla in the final post NACT surgical
specimen. Lesions with residual DCIS but no invasion
were therefore counted as a pCR.
Analysis was performed both for the whole study
group and by tumour immunophenotype. Owing to
small numbers in some subsets, data were reviewed and
grouped for statistical analysis. For US posterior effect,
the results were similar for enhancement and no effect
thus the data were grouped into shadowing vs non-
shadowing. Similarly, the results for hyperechoic and
heterogeneous lesional echo pattern were similar and
therefore echo pattern was analysed as hypoechoic vs
non-hypoechoic. Univariate analysis of categorical data
was performed using chi square, and continuous data
using ROC analysis. Multivariate analysis was performed
using a logistic regression model. Medcalc software was
used for statistical analysis.
Results
Two hundred twenty-two women were included with an
average age of 52.0 years (range: 24–79 years). Age was
not associated with pCR (area under the curve for whole
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group 0.55, p = 0.3). Of the total cancers, 83 (37%) were
triple negative (TN), 61 (27%) ER positive/HER-2 nega-
tive and 78 (35%) HER-2 positive.
Complete pathological response was achieved in 46
(21%) patients. Within the subgroups, similar rates of
pCR were seen in the TN and HER-2 positive groups;
(19/83) 22.9% and (23/78) 29.4% respectively. By con-
trast, only four (6.6%) patients in the ER positive HER-2
negative group achieved a pCR rendering subgroup ana-
lysis of these women impracticable.
The majority (154, 69%) of tumours were estimated
grade 3 on core biopsy, 66 (30%) were grade 2 and 2
(1%) grade 1. Owing to the very low numbers in the
grade 1 group, the data were combined with the grade 2
group for further analysis. Complete response was
achieved significantly more frequently with core biopsy
grade 3 tumours than in grade 1 & 2 tumours; 26% vs
9% respectively (p = 0.0044). However, grade did not re-
main significant in subgroup analysis of TN and HER-2
positive cancers.
One patient was unable to have a MMG at diagnosis,
while all patients underwent US. The combined results
of the two readers are considered, thus there are 442
MMG and 444 US interpretations. On univariate ana-
lysis of the whole group data absence of posterior sha-
dowing on ultrasound (76 of 291; 26% vs. 16 of 153;
10%, p < 0.001) was associated with pCR. The presence
of distal enhancement on ultrasound was not associated
with pCR. Figure 1a illustrates posterior shadowing, this
is the ultrasound imaging of a 56-year-old patient, who
died 2 years after diagnosis. By contrast Fig. 1b illustrates
a tumour demonstrating no posterior effect, this tumour
had a complete response to NACT and the patient re-
mains metastasis free 6 years after diagnosis. The ab-
sence of spiculation on mammography (85 of 321; 27%
vs. 7 of 121; 6%, p < 0.001) was also significantly associ-
ated with pCR (see Table 1). Examples of spiculated and
non-spiculated masses are given in Fig. 2.
The presence of a circumscribed margin (26 of 98;
27% vs. 66 of 346; 19%, p = 0.11), the echo pattern
(hypoechoic 67 of 308; 22% vs. non-hypoechoic 25 of
136; 18%, p = 0.4), size (area under curve 0.059; p =
0.059) on US, and mammographic microcalcification (25
of 151; 17% vs. 67 of 291; 23%, p = 0.11) on mammog-
raphy were not significantly associated with response to
NACT.
The absence of shadowing and spiculation remained
highly significant predictors of pCR on univariate ana-
lysis of the HER-2 positive group, in addition to small
ultrasound size (AUC = 0.713, p < 0.001) (Fig. 2) and
absence of microcalcification (29 of 74; 39% vs. 17 of 80;
21% p < 0.02) (Table 2). By contrast, no feature (includ-
ing US size) was significantly associated with response in
TN tumours (Table 3).
For the entire cohort, absence of spiculation and core
grade remained significant on multivariate analysis
(Table 4). Within the HER-2 positive group; size and ab-
sence of spiculation remained significant (Table 5).
Discussion
Neoadjuvant chemotherapy is used to treat increasing
numbers of women with breast cancer, especially those
with locally advanced disease. Selecting patients most
likely to derive benefit from treatment is essential. We
have demonstrated that baseline imaging features on
both US and mammography are associated with pCR
rates, and therefore may be a useful tool in identifying
patients who will respond well. Key imaging features in-
cluded absence of posterior shadowing on ultrasound
and the absence of spiculation on mammography for
both the whole group and the HER-2 positive sub-
group. Along with core biopsy grade, absence of spicula-
tion remained significantly correlated with pCR on
multivariate analysis of whole group data. In the HER-2
positive subgroup, mammographic spiculation and large
ultrasound size were significantly associated with
Fig. 1 a Illustrates the appearance of posterior shadowing on ultrasound of an invasive carcinoma. The patient died from metastatic breast
cancer, less than 2 years after diagnosis. b Shows a grade 3 invasive ductal carcinoma, the patient remains metastasis free 6 years post diagnosis
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residual disease on multivariate analysis. Whilst there
was a trend towards an association of absence of sha-
dowing and absence of spiculation with pCR in the TN
group, these were not statistically significant.
Immunophenotype and grade
It is widely accepted that the histological subtype and
grade of tumour affects the likelihood of response to
NACT. In agreement with previous published work, we
found that pCR occurred most commonly in high grade
tumours [9–11]. This association remained significant
on multivariate analysis of whole group data but was lost
on subgroup analysis, perhaps due to the relatively small
numbers. In a meta-analysis of 30 studies with approxi-
mately 1000 subjects, Houssami et al demonstrated an
independent association between breast cancer subtype
and pCR, with odds of pCR highest in the HER-2 posi-
tive and TN subtypes [12]. Our findings are congruent
with their study, which showed a pooled pCR of 19%
and pCR for the subtypes: HER-2+ 29%, TN 31% and
HR+/HER-2- 9% respectively. The lower pCR rates
amongst ER positive tumours may be partly due to the
correlation between ER-positivity and lower tumour
grade [9].
Gene expression and radiological correlates
Several molecular assays have been developed to predict
likelihood of disease recurrence and/or response to neo-
adjuvant chemotherapy, including Oncotype DX and
MammaPrint/BluePrint [1]. OncotypeDX is based on an
expression profile of 21 genes and generates a predicted
recurrence score (ODRS). A high RS has shown poten-
tial for predicting pCR in patients with HER-2 negative
tumours [3]. Interestingly, higher ODRS have demon-
strated a correlation with an oval mass at mammography
and US posterior enhancement [13].
Spiculation
Spiculated margins at mammography are present signifi-
cantly more frequently in low grade tumours [14, 15]. It
has been postulated that this is due to the desmoplastic
reaction more frequently provoked by low grade tu-
mours [15] and ER positive (luminal A type) tumours
[16]. These tumour subtypes also tend to respond less
well to NACT. By contrast, triple negative tumours,
which more frequently respond to NACT are predomin-
antly high grade and infrequently spiculate [17, 18]. Fur-
thermore, it has been demonstrated that a pCR is more
likely in lesions that are well defined, oval or round than
in those that are diffuse or irregular [5, 6]. Therefore the
correlation we have identified between the presence of
spiculation and lower rates of pCR is perhaps not
surprising.
Absence of posterior shadowing
It has previously been demonstrated that low grade tu-
mours tend to produce acoustic shadowing, whilst 36% of
Table 1 Rates of pathological complete response according to
selected baseline radiological feature for all tumours
pCR Non pCR % pCR p value
No shadowing 76 215 26.1
Shadowing 16 137 10.5 < 0.001
Hypoechoic 67 241 21.8
Non-hypoechoic 25 111 18.4 0.42
Circumscribed 26 72 26.5
Not circumscribed 66 280 19.1 0.11
Calcification 25 126 16.6
No calcification 67 224 23.0 0.11
Spiculation 7 114 5.8
No spiculation 85 236 26.5 < 0.001
Size AUC 0.588 0.059
Fig. 2 a Left MLO and CC views spiculate mass due to a grade 2 invasive ductal carcinoma. b Right MLO and CC views illustrating a non-
spiculate mass, this was a grade 3 invasive ductal carcinoma
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high-grade tumours demonstrate acoustic enhancement
on ultrasound examination [14]. Given that it is widely ac-
cepted that low grade tumours are less likely to respond
to NACT, [9–11] this may explain the correlation with ab-
sence of posterior shadowing and pCR in our study. This
correlation is lost on multivariate analysis. This may be
explained by the association between tumour grade and
posterior acoustic shadowing.
Size
Although not specific to ultrasound, there is evidence
that smaller tumours (defined as T1 or ≤ 2 cm) are sig-
nificantly more likely to achieve a complete response [9].
A recent study looked at correlations between initial
tumour size and pCR following NACT. Tumour size
was taken as the largest dimension on pre-treatment im-
aging (mammography, ultrasound, MRI, PET-CT, PET-
mammography or CT). On univariate analysis, the prob-
ability of pCR significantly decreased with increasing
tumour size in the basal and HER-2 subgroups, however
in multivariate logistic regression analysis this correl-
ation was lost for all subgroups [19]. This is at slight
variance to our findings for whole group and HER-2
positive tumours, with ultrasound size correlating with
pCR on univariate analysis and remaining significant in
multivariate analysis of HER-2 positive group. Whilst
the basal status of the tumours in our series is unknown,
there is at least 70% concordance between triple negative
and basal tumours [20]. It is of note that by contrast we
found no hint of a relationship between US size and re-
sponse in the TN sub-group. Other studies have shown
little or no relationship between size and survival in TN
breast cancer, particularly in those expressing basal cyto-
keratins [21]. This suggests that innate characteristics of
the tumour are more important than size and stage in
determining the outcome of TN tumours.
Microcalcifications
On univariate analysis, in the HER-2 positive subgroup,
microcalcification was a negative predictor for pCR, al-
though this did not remain significant on multivariate
analysis. This is consistent with existing evidence that
comedo-type, casting and pleomorphic microcalcifica-
tions on initial mammography are associated with
poorer prognosis [22–26]. Interestingly, in contrast to
two recent studies, we found no correlation between
microcalcification and poorer response to NACT in the
TN cancers [7, 8]. This may be due to the differing defi-
nitions of complete response; whilst in our study pCR is
considered the absence of invasive disease the previous
studies considered complete response to be the absence
of both invasive and in-situ disease. Microcalcification is
commonly associated with the presence of ductal carcin-
oma in situ (DCIS). The lack of correlation may also be
related to the relatively small proportion of TN
Table 4 Final multivariate model for the whole cohort
Odds Ratio 95% CI p
Shadowing 1.66 0.88–3.13 0.12
Spiculation 3.70 1.57–8.74 0.003
Core grade 0.38 0.20–0.73 0.004
Table 5 Final multivariate model for HER-2 positive tumours
Odds Ratio 95% CI p
Shadowing 2.42 0.95–6.20 0.07
Calcification 1.35 0.59–3.11 0.48
Spiculation 9.00 1.90–42.6 0.006
Size 1.10 1.04–1.16 0.001
Core grade 0.93 0.28–3.10 0.90
Table 3 Rates of pathological complete response according to
selected baseline radiological feature for TN tumours
pCR Non pCR % pCR p value
No shadowing 35 107 24.6
Shadowing 3 21 12.5 0.19
Hypoechoic 24 94 20.3
Non-hypoechoic 14 34 29.2 0.22
circumscribed 16 56 22.2
Not circumscribed 22 72 23.4 0.86
calcification 8 28 22.2
No calcification 30 100 23.1 1
spiculation 2 12 14.3
No spiculation 36 116 23.7 0.42
Size AUC 0.525 0.75
Table 2 Rates of pathological complete response according to
selected baseline radiological feature for HER-2 positive tumours
pCR Non pCR % pCR p value
No shadowing 37 59 38.5
Shadowing 9 51 15.0 0.002
Hypoechoic 37 76 32.7
Non-hypoechoic 9 34 20.9 0.15
circumscribed 10 12 45.4
Not circumscribed 36 98 26.9 0.08
calcification 17 63 21.3
No calcification 29 45 39.2 0.02
spiculation 2 37 5.1
No spiculation 44 71 38.3 < 0.001
ER + ve 12 40
ER -ve 11 15 0.08
Size AUC = 0.713 < 0.001
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demonstrating microcalcification on mammographic in-
terpretation; 36/166, 22%.
Limitations
This was a single centre study with relatively low num-
bers, particularly in certain immunophenotypic sub-
groups. The rate of pCR is also low, probably because
NACT is only given in our centre for large tumours
and/or node positive patients. The findings of this study
may therefore not reflect what is found when NACT is
given to smaller tumours on the basis of immunopheno-
type. Some of the factors which lost significance on
multivariate analysis may be of interest as the loss of sig-
nificance could reflect small numbers rather than lack of
an effect.
Conclusion
We have shown that pCR is less likely in tumours with
mammographic spiculation. Furthermore, smaller ultra-
sound size is a positive predictor of response to NACT
in HER-2 positive tumours. These findings may be im-
portant in assisting decision-making regarding offering
breast cancer patients NACT.
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